酪氨酸激酶抑制剂对肾癌免疫微环境的调节及其机制  

Tyrosine kinase inhibitor regulates the immune micro-environment of renal cell carcinoma and its mechanisms

作　　者：赵奇[1] 胡骁轶[1] 郭剑明[1] 王国民[1] 

机构地区：[1]复旦大学附属中山医院泌尿外科,上海200032

出　　处：《复旦学报（医学版）》2015年第4期555-559,共5页Fudan University Journal of Medical Sciences

基　　金：国家自然科学基金(81472376)~~

摘　　要：酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)是转移性肾癌的标准治疗方案。最新的研究发现,TKI不仅可以抑制肿瘤血管形成,还对肾癌免疫微环境起到调节作用。肾癌及其周围组织所形成的抑制性的免疫微环境是疾病进展、治疗耐受的重要原因。TKI通过阻断磷酸化信号转导子及转录激活因子3(signal transducer and activator of transcription 3,STAT3)、粒细胞巨噬细胞集落刺激因子(granulocyte macrophage colony stimulating factor,GM-CSF)等信号通路,减少具有免疫抑制功能的骨髓源性抑制细胞(myeloid-derived suppressor cell,MDSC),加强自然杀伤性T细胞功能。TKI还可以抑制调节性T细胞(regulatory T cells,Treg),起到增强细胞免疫的作用。TKI联合免疫治疗可能成为治疗转移性肾癌的新趋势。carcinoma. Tyrosine kinase inhibitors （TKI） is the standard treatment for metastasis of renal cell The new study found that TKI not only can inhibit tumor angiogenesis, but also play a regulatory role in renal carcinoma immune microenvironment. The suppressive immune microenvironment of renal cell carcinoma and its surrounding tissue is an important cause of disease progression and therapeutic tolerance. By blocking signal transducer and activator of transcription 3 （STAT3） and granulocyte macrophage colony sitmulating factor （GM-CSF） signal pathway, TKI reduce myeloid-derived suppressor cell （MDSC） and strengthen the natural killer T cell function. TKI can also inhibit the regulatory T cells（Treg） to enhance the cellular immune function. TKI combined immune therapy may become a new trend in the treatment of metastatic renal cell carcinoma.

关 键 词：酪氨酸激酶抑制剂 肾细胞癌 免疫微环境 骨髓源性抑制细胞 

分 类 号：R737.11[医药卫生—肿瘤]